The rate of positive chromogranin A is 100% in NET G3 and 88.6% in NEC G3, with positive synaptophysin rates of 95.2% and 93.8%, median Ki67-LI values of 28.5% and 80.0%, loss of retinoblastoma protein (Rb) expression in 0% and 54.5%, presence of a KRAS gene mutation in 0% and 48.7%, loss of Rb expression with a KRAS mutation in 0% and 30%, and p53 expression in 0% and 75%, respectively [4, 5]. The gene discussed is RB1; the disease is neuroendocrine carcinoma.